Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweep
Phase 3positivebitopertinPositive
AI Analysis
Summary
Disc Medicine's bitopertin, rejected by the FDA in February, posted positive Phase 3 results in erythropoietic protoporphyria, significantly reducing a key biomarker and increasing sun and light tolerance time. The data sets up an FDA resubmission.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Bitopertin significantly reduced a key disease biomarker and significantly increased time patients with erythropoietic protoporphyria could spend in sun and artificial light in a 'clean' Phase 3 sweep, setting up an FDA re-do following the February rejection.
Importance:8/10
Sentiment:
0.70
Phase 3rare diseaseerythropoietic protoporphyriaEPPFDA rejectionresubmissionbitopertinpositive data
Related Companies
Read the original article
Published by BioSpace on October 19, 2026 11:02 AM